Met Life Investment Management, LLC Intellia Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 55,696 shares of NTLA stock, worth $778,073. This represents 0.01% of its overall portfolio holdings.

Number of Shares
55,696
Previous 55,696 -0.0%
Holding current value
$778,073
Previous $1.25 Million 8.19%
% of portfolio
0.01%
Previous 0.01%

Shares

51 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$20.02 - $27.22 $184,184 - $250,424
9,200 Added 19.79%
55,696 $1.25 Million
Q1 2024

May 14, 2024
BUY
$23.82 - $32.8 $1.11 Million - $1.53 Million
46,496 New
46,496 $1.28 Million
Q3 2023

May 09, 2024
BUY
$31.62 - $45.78 $77,943 - $112,847
2,465 Added 5.6%
46,496 $1.47 Million
Q2 2023

Apr 29, 2024
BUY
$34.58 - $46.03 $1.61 Million - $2.14 Million
46,496 New
46,496 $1.9 Million
Q2 2023

Aug 10, 2023
BUY
$34.58 - $46.03 $85,239 - $113,463
2,465 Added 5.6%
46,496 $1.9 Million
Q1 2023

May 09, 2024
BUY
$33.3 - $44.82 $1.47 Million - $1.97 Million
44,031 New
44,031 $1.64 Billion
Q4 2022

May 10, 2024
BUY
$33.21 - $62.69 $130,515 - $246,371
3,930 Added 9.8%
44,031 $1.54 Million
Q4 2022

Mar 22, 2023
BUY
$33.21 - $62.69 $130,515 - $246,371
3,930 Added 9.8%
44,031 $1.54 Million
Q4 2022

Feb 15, 2023
BUY
$33.21 - $62.69 $130,515 - $246,371
3,930 Added 9.8%
44,031 $1.54 Million
Q3 2022

May 10, 2024
BUY
$53.92 - $71.7 $49,444 - $65,748
917 Added 2.34%
40,101 $2.24 Million
Q3 2022

Jun 14, 2023
SELL
$53.92 - $71.7 $211,905 - $281,781
-3,930 Reduced 8.93%
40,101 $2.24 Million
Q3 2022

Mar 22, 2023
BUY
$53.92 - $71.7 $49,444 - $65,748
917 Added 2.34%
40,101 $2.24 Million
Q3 2022

Nov 14, 2022
BUY
$53.92 - $71.7 $49,444 - $65,748
917 Added 2.34%
40,101 $2.24 Million
Q2 2022

May 10, 2024
BUY
$38.49 - $76.21 $70,128 - $138,854
1,822 Added 4.88%
39,184 $2.03 Million
Q2 2022

Jun 20, 2023
SELL
$38.49 - $76.21 $186,561 - $369,389
-4,847 Reduced 11.01%
39,184 $2.03 Million
Q2 2022

Mar 22, 2023
BUY
$38.49 - $76.21 $70,128 - $138,854
1,822 Added 4.88%
39,184 $2.03 Million
Q2 2022

Aug 11, 2022
BUY
$38.49 - $76.21 $70,128 - $138,854
1,822 Added 4.88%
39,184 $2.03 Million
Q1 2022

May 10, 2024
BUY
$58.27 - $118.99 $2.18 Million - $4.45 Million
37,362 New
37,362 $2.72 Million
Q1 2022

Jun 20, 2023
SELL
$58.27 - $118.99 $388,602 - $793,544
-6,669 Reduced 15.15%
37,362 $2.72 Million
Q1 2022

Mar 22, 2023
BUY
$58.27 - $118.99 $769,688 - $1.57 Million
13,209 Added 54.69%
37,362 $2.72 Million
Q1 2022

May 12, 2022
BUY
$58.27 - $118.99 $769,688 - $1.57 Million
13,209 Added 54.69%
37,362 $2.72 Million
Q4 2021

Jun 21, 2023
SELL
$100.76 - $138.36 $2 Million - $2.75 Million
-19,878 Reduced 45.15%
24,153 $2.86 Million
Q3 2021

May 17, 2024
BUY
$132.37 - $176.78 $181,214 - $242,011
1,369 Added 6.01%
24,153 $3.24 Million
Q3 2021

Jun 21, 2023
SELL
$132.37 - $176.78 $2.63 Million - $3.51 Million
-19,878 Reduced 45.15%
24,153 $3.24 Million
Q3 2021

Mar 22, 2023
BUY
$132.37 - $176.78 $181,214 - $242,011
1,369 Added 6.01%
24,153 $3.24 Million
Q3 2021

Nov 15, 2021
BUY
$132.37 - $176.78 $181,214 - $242,011
1,369 Added 6.01%
24,153 $3.24 Million
Q2 2021

May 17, 2024
BUY
$60.88 - $161.91 $172,960 - $459,986
2,841 Added 14.25%
22,784 $3.69 Million
Q2 2021

Jun 21, 2023
SELL
$60.88 - $161.91 $1.29 Million - $3.44 Million
-21,247 Reduced 48.25%
22,784 $3.69 Million
Q2 2021

Mar 22, 2023
BUY
$60.88 - $161.91 $172,960 - $459,986
2,841 Added 14.25%
22,784 $3.69 Million
Q2 2021

Aug 16, 2021
BUY
$60.88 - $161.91 $172,960 - $459,986
2,841 Added 14.25%
22,784 $3.69 Million
Q1 2021

May 17, 2024
SELL
$46.59 - $83.68 $1.24 Million - $2.22 Million
-26,553 Reduced 57.11%
19,943 $1.6 Million
Q1 2021

Jun 26, 2023
SELL
$46.59 - $83.68 $1.12 Million - $2.02 Million
-24,088 Reduced 54.71%
19,943 $1.6 Billion
Q4 2020

Jun 22, 2023
SELL
$18.83 - $63.53 $453,577 - $1.53 Million
-24,088 Reduced 54.71%
19,943 $1.08 Million
Q3 2020

Jun 26, 2023
SELL
$17.47 - $24.93 $420,817 - $600,513
-24,088 Reduced 54.71%
19,943 $396,000
Q2 2020

May 24, 2024
SELL
$11.14 - $22.87 $295,800 - $607,267
-26,553 Reduced 57.11%
19,943 $419 Million
Q2 2020

Jun 26, 2023
SELL
$11.14 - $22.87 $268,340 - $550,892
-24,088 Reduced 54.71%
19,943 $419,000
Q2 2020

Mar 22, 2023
BUY
$11.14 - $22.87 $46,810 - $96,099
4,202 Added 26.69%
19,943 $419,000
Q2 2020

Aug 14, 2020
BUY
$11.14 - $22.87 $46,810 - $96,099
4,202 Added 26.69%
19,943 $419,000
Q1 2020

Jul 12, 2023
SELL
$9.44 - $15.58 $267,057 - $440,758
-28,290 Reduced 64.25%
15,741 $192,000
Q4 2019

Jul 12, 2023
SELL
$10.43 - $17.67 $295,064 - $499,884
-28,290 Reduced 64.25%
15,741 $230,000
Q3 2019

Jul 12, 2023
SELL
$13.07 - $18.51 $369,750 - $523,647
-28,290 Reduced 64.25%
15,741 $210,000
Q2 2019

Jul 12, 2023
SELL
$13.88 - $18.41 $392,665 - $520,818
-28,290 Reduced 64.25%
15,741 $257,000
Q1 2019

Jul 13, 2023
SELL
$12.79 - $17.62 $361,829 - $498,469
-28,290 Reduced 64.25%
15,741 $268,000
Q4 2018

Jul 13, 2023
SELL
$11.39 - $27.13 $322,223 - $767,507
-28,290 Reduced 64.25%
15,741 $214,000
Q4 2018

Mar 22, 2023
SELL
$11.39 - $27.13 $98,887 - $235,542
-8,682 Reduced 35.55%
15,741 $214,000
Q4 2018

Feb 14, 2019
SELL
$11.39 - $27.13 $98,887 - $235,542
-8,682 Reduced 35.55%
15,741 $215,000
Q3 2018

Jul 13, 2023
SELL
$25.78 - $32.6 $729,316 - $922,254
-28,290 Reduced 64.25%
15,741 $450,000
Q3 2018

Mar 22, 2023
SELL
$25.78 - $32.6 $505,494 - $639,220
-19,608 Reduced 44.53%
24,423 $698,000
Q3 2018

Nov 14, 2018
BUY
$25.78 - $32.6 $223,821 - $283,033
8,682 Added 55.16%
24,423 $699,000
Q2 2018

Aug 15, 2018
BUY
$20.02 - $30.79 $163,042 - $250,753
8,144 Added 107.2%
15,741 $431,000
Q4 2017

Feb 15, 2018
BUY
$17.39 - $31.12 $132,111 - $236,418
7,597
7,597 $146,000

Others Institutions Holding NTLA

# of Institutions
313
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.06B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email